Stem definition | Drug id | CAS RN |
---|---|---|
spasmolytics with a papaverine-like action | 2028 | 5633-20-5 |
Dose | Unit | Route |
---|---|---|
15 | mg | O |
3.90 | mg | TD |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.80 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.93 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 6 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.85 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 5.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 7.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 16, 1975 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary tract infection | 268.39 | 10.51 | 576 | 42350 | 239937 | 56009204 |
Multiple sclerosis relapse | 260.12 | 10.51 | 239 | 42687 | 44664 | 56204477 |
Fall | 231.07 | 10.51 | 696 | 42230 | 356814 | 55892327 |
Multiple sclerosis | 157.10 | 10.51 | 146 | 42780 | 27656 | 56221485 |
Urinary incontinence | 138.28 | 10.51 | 140 | 42786 | 29445 | 56219696 |
Contraindicated product administered | 127.71 | 10.51 | 3 | 42923 | 186283 | 56062858 |
Systemic lupus erythematosus | 109.68 | 10.51 | 7 | 42919 | 180071 | 56069070 |
Rheumatoid arthritis | 107.48 | 10.51 | 81 | 42845 | 382523 | 55866618 |
Dry mouth | 104.82 | 10.51 | 181 | 42745 | 64024 | 56185117 |
Application site erythema | 99.92 | 10.51 | 55 | 42871 | 4545 | 56244596 |
Maternal exposure during pregnancy | 93.52 | 10.51 | 16 | 42910 | 189537 | 56059604 |
Synovitis | 88.06 | 10.51 | 10 | 42916 | 161295 | 56087846 |
Glossodynia | 84.37 | 10.51 | 9 | 42917 | 152449 | 56096692 |
Gait disturbance | 80.83 | 10.51 | 291 | 42635 | 163030 | 56086111 |
Joint swelling | 80.48 | 10.51 | 62 | 42864 | 289738 | 55959403 |
Vaginal flatulence | 71.95 | 10.51 | 25 | 42901 | 668 | 56248473 |
Balance disorder | 67.09 | 10.51 | 167 | 42759 | 76353 | 56172788 |
Urine analysis abnormal | 62.39 | 10.51 | 41 | 42885 | 4676 | 56244465 |
Abdominal discomfort | 62.10 | 10.51 | 72 | 42854 | 277202 | 55971939 |
Micturition urgency | 59.27 | 10.51 | 51 | 42875 | 8730 | 56240411 |
Treatment failure | 57.56 | 10.51 | 29 | 42897 | 170363 | 56078778 |
Drug intolerance | 56.92 | 10.51 | 71 | 42855 | 264747 | 55984394 |
Exposure during pregnancy | 56.27 | 10.51 | 17 | 42909 | 136325 | 56112816 |
Pollakiuria | 54.79 | 10.51 | 81 | 42845 | 25121 | 56224020 |
Neurogenic bladder | 54.44 | 10.51 | 32 | 42894 | 2997 | 56246144 |
Pericarditis | 54.12 | 10.51 | 9 | 42917 | 108914 | 56140227 |
Hepatic enzyme increased | 52.38 | 10.51 | 33 | 42893 | 171351 | 56077790 |
Infusion related reaction | 51.52 | 10.51 | 50 | 42876 | 208881 | 56040260 |
Proctitis | 51.21 | 10.51 | 29 | 42897 | 2531 | 56246610 |
Application site pruritus | 50.03 | 10.51 | 33 | 42893 | 3786 | 56245355 |
Hypertonic bladder | 49.97 | 10.51 | 31 | 42895 | 3201 | 56245940 |
Laboratory test abnormal | 48.91 | 10.51 | 76 | 42850 | 24619 | 56224522 |
Bladder disorder | 46.98 | 10.51 | 43 | 42883 | 7981 | 56241160 |
Off label use | 44.50 | 10.51 | 246 | 42680 | 555934 | 55693207 |
Mental status changes | 44.15 | 10.51 | 92 | 42834 | 37409 | 56211732 |
Secondary progressive multiple sclerosis | 42.99 | 10.51 | 21 | 42905 | 1354 | 56247787 |
Wound | 42.03 | 10.51 | 27 | 42899 | 138777 | 56110364 |
Arthropathy | 41.66 | 10.51 | 55 | 42871 | 200220 | 56048921 |
Product adhesion issue | 40.78 | 10.51 | 31 | 42895 | 4452 | 56244689 |
Female genital tract fistula | 40.72 | 10.51 | 31 | 42895 | 4461 | 56244680 |
Duodenal ulcer perforation | 40.58 | 10.51 | 3 | 42923 | 68339 | 56180802 |
Muscular weakness | 40.16 | 10.51 | 172 | 42754 | 104280 | 56144861 |
Radiculopathy | 38.43 | 10.51 | 33 | 42893 | 5632 | 56243509 |
White blood cells urine positive | 36.77 | 10.51 | 30 | 42896 | 4772 | 56244369 |
Depression | 36.63 | 10.51 | 249 | 42677 | 179868 | 56069273 |
Bladder spasm | 34.85 | 10.51 | 19 | 42907 | 1540 | 56247601 |
Product use issue | 33.90 | 10.51 | 56 | 42870 | 185985 | 56063156 |
Hallucination | 33.72 | 10.51 | 98 | 42828 | 49051 | 56200090 |
Swelling | 33.62 | 10.51 | 84 | 42842 | 239687 | 56009454 |
Culture urine positive | 33.43 | 10.51 | 25 | 42901 | 3503 | 56245638 |
Arthralgia | 32.81 | 10.51 | 236 | 42690 | 501433 | 55747708 |
Escherichia urinary tract infection | 32.53 | 10.51 | 41 | 42885 | 10934 | 56238207 |
Incontinence | 31.66 | 10.51 | 40 | 42886 | 10695 | 56238446 |
Urine leukocyte esterase positive | 31.51 | 10.51 | 23 | 42903 | 3105 | 56246036 |
Asthenia | 31.29 | 10.51 | 399 | 42527 | 342574 | 55906567 |
Urinary retention | 30.87 | 10.51 | 67 | 42859 | 28007 | 56221134 |
Malignant neoplasm progression | 30.67 | 10.51 | 9 | 42917 | 73578 | 56175563 |
Dysuria | 30.06 | 10.51 | 70 | 42856 | 30659 | 56218482 |
Application site rash | 29.49 | 10.51 | 20 | 42906 | 2403 | 56246738 |
Muscle injury | 29.28 | 10.51 | 3 | 42923 | 52497 | 56196644 |
Cystitis | 29.16 | 10.51 | 93 | 42833 | 48945 | 56200196 |
Therapeutic product effect decreased | 29.05 | 10.51 | 53 | 42873 | 169399 | 56079742 |
Cerebral atrophy | 28.83 | 10.51 | 26 | 42900 | 4734 | 56244407 |
Stomatitis | 28.51 | 10.51 | 30 | 42896 | 120780 | 56128361 |
Vaginal discharge | 28.48 | 10.51 | 29 | 42897 | 6134 | 56243007 |
Discomfort | 28.39 | 10.51 | 40 | 42886 | 141721 | 56107420 |
Bacterial test | 28.19 | 10.51 | 15 | 42911 | 1158 | 56247983 |
Urinary sediment present | 27.28 | 10.51 | 18 | 42908 | 2066 | 56247075 |
Muscle spasticity | 27.12 | 10.51 | 52 | 42874 | 19908 | 56229233 |
Blister | 26.88 | 10.51 | 26 | 42900 | 108861 | 56140280 |
Urine abnormality | 26.47 | 10.51 | 29 | 42897 | 6670 | 56242471 |
Band neutrophil percentage increased | 26.47 | 10.51 | 9 | 42917 | 225 | 56248916 |
Febrile neutropenia | 26.29 | 10.51 | 25 | 42901 | 105520 | 56143621 |
Monocyte percentage increased | 26.21 | 10.51 | 14 | 42912 | 1089 | 56248052 |
Red blood cells urine positive | 25.92 | 10.51 | 20 | 42906 | 2936 | 56246205 |
Hallucination, visual | 25.59 | 10.51 | 47 | 42879 | 17421 | 56231720 |
Decubitus ulcer | 25.06 | 10.51 | 34 | 42892 | 9741 | 56239400 |
Rash | 24.56 | 10.51 | 249 | 42677 | 492798 | 55756343 |
Lymphocyte count decreased | 24.49 | 10.51 | 61 | 42865 | 27878 | 56221263 |
Lymphocyte percentage decreased | 24.35 | 10.51 | 19 | 42907 | 2835 | 56246306 |
Alopecia | 23.83 | 10.51 | 129 | 42797 | 293329 | 55955812 |
Gait inability | 23.68 | 10.51 | 78 | 42848 | 41740 | 56207401 |
Constipation | 23.32 | 10.51 | 246 | 42680 | 201697 | 56047444 |
Myelocyte percentage increased | 23.30 | 10.51 | 8 | 42918 | 206 | 56248935 |
Nephrolithiasis | 23.30 | 10.51 | 72 | 42854 | 37263 | 56211878 |
Injection site scar | 22.99 | 10.51 | 12 | 42914 | 891 | 56248250 |
Band neutrophil count increased | 22.42 | 10.51 | 9 | 42917 | 362 | 56248779 |
Confusional state | 22.39 | 10.51 | 250 | 42676 | 207905 | 56041236 |
Lower respiratory tract infection | 22.38 | 10.51 | 33 | 42893 | 114761 | 56134380 |
Head injury | 22.26 | 10.51 | 55 | 42871 | 25011 | 56224130 |
Urine oxalate increased | 21.90 | 10.51 | 8 | 42918 | 248 | 56248893 |
Dysmetropsia | 21.52 | 10.51 | 6 | 42920 | 75 | 56249066 |
Crystal urine present | 21.44 | 10.51 | 14 | 42912 | 1579 | 56247562 |
Retinal depigmentation | 21.04 | 10.51 | 8 | 42918 | 278 | 56248863 |
Peripheral swelling | 20.85 | 10.51 | 100 | 42826 | 234626 | 56014515 |
Amnesia | 20.75 | 10.51 | 80 | 42846 | 46242 | 56202899 |
Memory impairment | 20.23 | 10.51 | 124 | 42802 | 86433 | 56162708 |
Nocturia | 20.20 | 10.51 | 26 | 42900 | 7080 | 56242061 |
Cerebrovascular accident | 20.01 | 10.51 | 137 | 42789 | 99133 | 56150008 |
Dizziness | 20.01 | 10.51 | 400 | 42526 | 375740 | 55873401 |
Thrombocytopenia | 19.64 | 10.51 | 47 | 42879 | 136177 | 56112964 |
Food refusal | 19.56 | 10.51 | 8 | 42918 | 338 | 56248803 |
Myelocyte count increased | 19.04 | 10.51 | 8 | 42918 | 362 | 56248779 |
Prescription drug used without a prescription | 18.69 | 10.51 | 14 | 42912 | 1966 | 56247175 |
Urinary tract infection bacterial | 18.69 | 10.51 | 20 | 42906 | 4480 | 56244661 |
Application site irritation | 18.60 | 10.51 | 13 | 42913 | 1639 | 56247502 |
Nasopharyngitis | 18.55 | 10.51 | 96 | 42830 | 220863 | 56028278 |
Chronic papillomatous dermatitis | 18.43 | 10.51 | 5 | 42921 | 56 | 56249085 |
Application site vesicles | 18.38 | 10.51 | 12 | 42914 | 1353 | 56247788 |
Psychotic symptom | 18.35 | 10.51 | 12 | 42914 | 1357 | 56247784 |
Impaired self-care | 17.76 | 10.51 | 13 | 42913 | 1763 | 56247378 |
Faecaloma | 17.75 | 10.51 | 25 | 42901 | 7416 | 56241725 |
Injection related reaction | 17.73 | 10.51 | 9 | 42917 | 630 | 56248511 |
Lymphopenia | 17.28 | 10.51 | 39 | 42887 | 16735 | 56232406 |
Cardiac failure congestive | 17.06 | 10.51 | 120 | 42806 | 87600 | 56161541 |
Hypersensitivity | 17.01 | 10.51 | 120 | 42806 | 256288 | 55992853 |
Product administered at inappropriate site | 16.99 | 10.51 | 15 | 42911 | 2655 | 56246486 |
Drug abuse | 16.85 | 10.51 | 16 | 42910 | 67594 | 56181547 |
Mixed incontinence | 16.74 | 10.51 | 5 | 42921 | 81 | 56249060 |
Dementia | 16.69 | 10.51 | 39 | 42887 | 17119 | 56232022 |
Resting tremor | 16.65 | 10.51 | 9 | 42917 | 717 | 56248424 |
Specific gravity urine decreased | 16.43 | 10.51 | 9 | 42917 | 736 | 56248405 |
Neutrophil percentage increased | 16.31 | 10.51 | 15 | 42911 | 2801 | 56246340 |
Pyelonephritis | 16.22 | 10.51 | 37 | 42889 | 15987 | 56233154 |
Red blood cell sedimentation rate increased | 16.16 | 10.51 | 4 | 42922 | 36619 | 56212522 |
Lagophthalmos | 15.98 | 10.51 | 7 | 42919 | 351 | 56248790 |
General physical health deterioration | 15.93 | 10.51 | 71 | 42855 | 169939 | 56079202 |
Urine odour abnormal | 15.93 | 10.51 | 21 | 42905 | 5853 | 56243288 |
Urinary tract infection pseudomonal | 15.80 | 10.51 | 9 | 42917 | 794 | 56248347 |
Dermatitis contact | 15.72 | 10.51 | 27 | 42899 | 9500 | 56239641 |
Psoriatic arthropathy | 15.70 | 10.51 | 20 | 42906 | 73988 | 56175153 |
Somnolence | 15.67 | 10.51 | 192 | 42734 | 163221 | 56085920 |
Stress urinary incontinence | 15.52 | 10.51 | 13 | 42913 | 2145 | 56246996 |
Peroneal nerve palsy | 15.39 | 10.51 | 18 | 42908 | 4443 | 56244698 |
Product complaint | 15.20 | 10.51 | 30 | 42896 | 11730 | 56237411 |
Body height decreased | 15.11 | 10.51 | 26 | 42900 | 9159 | 56239982 |
Impaired healing | 15.02 | 10.51 | 27 | 42899 | 86814 | 56162327 |
Therapeutic product effect incomplete | 14.95 | 10.51 | 37 | 42889 | 105994 | 56143147 |
Thyroglobulin increased | 14.42 | 10.51 | 4 | 42922 | 49 | 56249092 |
Hip fracture | 14.11 | 10.51 | 49 | 42877 | 26924 | 56222217 |
Abortion spontaneous | 13.95 | 10.51 | 8 | 42918 | 43745 | 56205396 |
Product dose omission issue | 13.77 | 10.51 | 226 | 42700 | 204527 | 56044614 |
Repetitive strain injury | 13.69 | 10.51 | 5 | 42921 | 155 | 56248986 |
Urinary tract disorder | 13.41 | 10.51 | 13 | 42913 | 2591 | 56246550 |
Seizure | 13.31 | 10.51 | 150 | 42776 | 124969 | 56124172 |
Vertigo | 13.27 | 10.51 | 79 | 42847 | 54493 | 56194648 |
Chronic obstructive pulmonary disease | 13.25 | 10.51 | 82 | 42844 | 57333 | 56191808 |
Feeling abnormal | 13.25 | 10.51 | 158 | 42768 | 133444 | 56115697 |
Open fracture | 13.23 | 10.51 | 6 | 42920 | 327 | 56248814 |
Haemoglobin urine present | 13.10 | 10.51 | 8 | 42918 | 803 | 56248338 |
Visual impairment | 12.99 | 10.51 | 99 | 42827 | 74103 | 56175038 |
Anaemia folate deficiency | 12.73 | 10.51 | 5 | 42921 | 190 | 56248951 |
Product closure removal difficult | 12.72 | 10.51 | 3 | 42923 | 18 | 56249123 |
Skin irritation | 12.70 | 10.51 | 23 | 42903 | 8432 | 56240709 |
Coordination abnormal | 12.62 | 10.51 | 29 | 42897 | 12592 | 56236549 |
Pain | 12.52 | 10.51 | 398 | 42528 | 662786 | 55586355 |
Anaphylactic reaction | 12.46 | 10.51 | 16 | 42910 | 58979 | 56190162 |
Central nervous system lesion | 12.42 | 10.51 | 25 | 42901 | 9913 | 56239228 |
Speech disorder | 12.34 | 10.51 | 59 | 42867 | 37434 | 56211707 |
Hallucinations, mixed | 12.28 | 10.51 | 16 | 42910 | 4408 | 56244733 |
Porphyria acute | 12.22 | 10.51 | 8 | 42918 | 906 | 56248235 |
Device expulsion | 12.19 | 10.51 | 4 | 42922 | 30445 | 56218696 |
Drug withdrawal syndrome neonatal | 12.19 | 10.51 | 11 | 42915 | 2005 | 56247136 |
Dysarthria | 12.14 | 10.51 | 61 | 42865 | 39489 | 56209652 |
Pregnancy | 12.11 | 10.51 | 5 | 42921 | 33028 | 56216113 |
Myocardial infarction | 12.09 | 10.51 | 116 | 42810 | 92754 | 56156387 |
Neutropenia | 12.02 | 10.51 | 71 | 42855 | 158096 | 56091045 |
Intentional overdose | 11.94 | 10.51 | 21 | 42905 | 68096 | 56181045 |
Sinusitis | 11.89 | 10.51 | 95 | 42831 | 197486 | 56051655 |
Incision site pruritus | 11.86 | 10.51 | 3 | 42923 | 25 | 56249116 |
Gastrointestinal disorder | 11.85 | 10.51 | 45 | 42881 | 112657 | 56136484 |
Klebsiella test positive | 11.80 | 10.51 | 8 | 42918 | 960 | 56248181 |
Oral candidiasis | 11.53 | 10.51 | 36 | 42890 | 18727 | 56230414 |
Interstitial lung disease | 11.52 | 10.51 | 16 | 42910 | 57047 | 56192094 |
Hepatic function abnormal | 11.48 | 10.51 | 6 | 42920 | 34552 | 56214589 |
Basophil count decreased | 11.47 | 10.51 | 4 | 42922 | 108 | 56249033 |
Therapy cessation | 11.33 | 10.51 | 46 | 42880 | 27218 | 56221923 |
Nitrite urine | 11.03 | 10.51 | 3 | 42923 | 34 | 56249107 |
Blood thyroid stimulating hormone decreased | 11.00 | 10.51 | 15 | 42911 | 4318 | 56244823 |
Bladder pain | 10.98 | 10.51 | 10 | 42916 | 1844 | 56247297 |
Progressive multiple sclerosis | 10.85 | 10.51 | 7 | 42919 | 774 | 56248367 |
Bone marrow failure | 10.83 | 10.51 | 4 | 42922 | 28282 | 56220859 |
Haematocrit decreased | 10.74 | 10.51 | 56 | 42870 | 36773 | 56212368 |
Intestinal pseudo-obstruction | 10.72 | 10.51 | 7 | 42919 | 790 | 56248351 |
Magnetic resonance imaging abnormal | 10.62 | 10.51 | 12 | 42914 | 2854 | 56246287 |
Anticholinergic syndrome | 10.62 | 10.51 | 10 | 42916 | 1924 | 56247217 |
Tri-iodothyronine increased | 10.52 | 10.51 | 4 | 42922 | 139 | 56249002 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary tract infection | 170.33 | 12.71 | 196 | 14898 | 76673 | 31605577 |
Dry mouth | 91.81 | 12.71 | 83 | 15011 | 24375 | 31657875 |
Confusional state | 82.29 | 12.71 | 190 | 14904 | 133144 | 31549106 |
Multiple sclerosis relapse | 68.44 | 12.71 | 52 | 15042 | 11995 | 31670255 |
Fall | 64.71 | 12.71 | 215 | 14879 | 185874 | 31496376 |
Multiple sclerosis | 48.55 | 12.71 | 36 | 15058 | 8001 | 31674249 |
Bladder spasm | 46.99 | 12.71 | 17 | 15077 | 831 | 31681419 |
Urinary retention | 43.42 | 12.71 | 66 | 15028 | 33659 | 31648591 |
Muscle spasticity | 40.37 | 12.71 | 28 | 15066 | 5607 | 31676643 |
Disorganised speech | 30.32 | 12.71 | 12 | 15082 | 752 | 31681498 |
Constipation | 28.70 | 12.71 | 126 | 14968 | 123865 | 31558385 |
Delirium | 27.65 | 12.71 | 61 | 15033 | 41360 | 31640890 |
Completed suicide | 25.92 | 12.71 | 99 | 14995 | 91415 | 31590835 |
Urinary incontinence | 25.32 | 12.71 | 36 | 15058 | 17284 | 31664966 |
Micturition urgency | 24.50 | 12.71 | 21 | 15073 | 5739 | 31676511 |
Daydreaming | 23.64 | 12.71 | 9 | 15085 | 508 | 31681742 |
Hallucination | 22.07 | 12.71 | 60 | 15034 | 46350 | 31635900 |
Neurogenic bladder | 21.44 | 12.71 | 12 | 15082 | 1647 | 31680603 |
Escherichia urinary tract infection | 21.13 | 12.71 | 15 | 15079 | 3115 | 31679135 |
Hypertonic bladder | 20.97 | 12.71 | 12 | 15082 | 1718 | 31680532 |
Nephrolithiasis | 20.24 | 12.71 | 42 | 15052 | 27297 | 31654953 |
Anticholinergic syndrome | 20.12 | 12.71 | 10 | 15084 | 1078 | 31681172 |
Dysuria | 19.99 | 12.71 | 39 | 15055 | 24255 | 31657995 |
Urosepsis | 19.60 | 12.71 | 26 | 15068 | 11694 | 31670556 |
Interstitial lung disease | 19.43 | 12.71 | 3 | 15091 | 61400 | 31620850 |
Perthes disease | 17.87 | 12.71 | 3 | 15091 | 3 | 31682247 |
Syncope | 17.77 | 12.71 | 84 | 15010 | 85098 | 31597152 |
Decubitus ulcer | 17.28 | 12.71 | 20 | 15074 | 7836 | 31674414 |
Vision blurred | 16.84 | 12.71 | 51 | 15043 | 41864 | 31640386 |
Gait disturbance | 16.59 | 12.71 | 77 | 15017 | 77418 | 31604832 |
Bladder catheterisation | 16.46 | 12.71 | 7 | 15087 | 527 | 31681723 |
Pollakiuria | 16.29 | 12.71 | 30 | 15064 | 17872 | 31664378 |
Cystitis interstitial | 15.67 | 12.71 | 5 | 15089 | 166 | 31682084 |
Dizziness | 15.62 | 12.71 | 154 | 14940 | 198993 | 31483257 |
Rib hypoplasia | 15.13 | 12.71 | 3 | 15091 | 12 | 31682238 |
Amnesia | 15.09 | 12.71 | 34 | 15060 | 23368 | 31658882 |
Implant site erosion | 14.81 | 12.71 | 4 | 15090 | 73 | 31682177 |
Cognitive disorder | 14.74 | 12.71 | 35 | 15059 | 24888 | 31657362 |
Mental status changes | 14.67 | 12.71 | 44 | 15050 | 35924 | 31646326 |
Granulocytopenia | 14.21 | 12.71 | 16 | 15078 | 6083 | 31676167 |
Pulmonary hypoplasia | 14.11 | 12.71 | 6 | 15088 | 452 | 31681798 |
Intestinal pseudo-obstruction | 14.08 | 12.71 | 9 | 15085 | 1574 | 31680676 |
Localised oedema | 13.96 | 12.71 | 12 | 15082 | 3290 | 31678960 |
Haematuria | 13.84 | 12.71 | 51 | 15043 | 46263 | 31635987 |
Balance disorder | 13.61 | 12.71 | 44 | 15050 | 37378 | 31644872 |
Abnormal behaviour | 13.59 | 12.71 | 33 | 15061 | 23795 | 31658455 |
Haemorrhage urinary tract | 13.28 | 12.71 | 9 | 15085 | 1736 | 31680514 |
Agitation | 13.24 | 12.71 | 56 | 15038 | 54113 | 31628137 |
Bladder disorder | 13.20 | 12.71 | 11 | 15083 | 2891 | 31679359 |
Hallucination, tactile | 13.19 | 12.71 | 5 | 15089 | 279 | 31681971 |
Tongue haemorrhage | 13.16 | 12.71 | 6 | 15088 | 534 | 31681716 |
Hepatitis acute | 12.98 | 12.71 | 16 | 15078 | 6693 | 31675557 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary tract infection | 369.55 | 10.71 | 615 | 45586 | 248154 | 70634089 |
Multiple sclerosis relapse | 276.34 | 10.71 | 227 | 45974 | 42790 | 70839453 |
Fall | 220.53 | 10.71 | 712 | 45489 | 443384 | 70438859 |
Multiple sclerosis | 142.92 | 10.71 | 124 | 46077 | 25161 | 70857082 |
Dry mouth | 139.08 | 10.71 | 199 | 46002 | 70258 | 70811985 |
Urinary incontinence | 94.68 | 10.71 | 120 | 46081 | 37722 | 70844521 |
Contraindicated product administered | 74.64 | 10.71 | 3 | 46198 | 134609 | 70747634 |
Confusional state | 68.83 | 10.71 | 366 | 45835 | 284032 | 70598211 |
Urine analysis abnormal | 65.44 | 10.71 | 44 | 46157 | 6110 | 70876133 |
Application site erythema | 62.85 | 10.71 | 39 | 46162 | 4722 | 70877521 |
Neurogenic bladder | 60.09 | 10.71 | 35 | 46166 | 3778 | 70878465 |
Bladder spasm | 57.74 | 10.71 | 28 | 46173 | 2085 | 70880158 |
Gait disturbance | 56.77 | 10.71 | 255 | 45946 | 184851 | 70697392 |
Micturition urgency | 55.05 | 10.71 | 51 | 46150 | 11263 | 70870980 |
Escherichia urinary tract infection | 54.06 | 10.71 | 53 | 46148 | 12554 | 70869689 |
Laboratory test abnormal | 53.97 | 10.71 | 75 | 46126 | 25748 | 70856495 |
Synovitis | 52.93 | 10.71 | 10 | 46191 | 129218 | 70753025 |
Treatment failure | 51.45 | 10.71 | 15 | 46186 | 144127 | 70738116 |
Rheumatoid arthritis | 51.32 | 10.71 | 69 | 46132 | 291736 | 70590507 |
Urinary retention | 48.14 | 10.71 | 106 | 46095 | 52414 | 70829829 |
Mental status changes | 47.61 | 10.71 | 118 | 46083 | 62983 | 70819260 |
Hypertonic bladder | 47.45 | 10.71 | 30 | 46171 | 3753 | 70878490 |
Muscle spasticity | 46.98 | 10.71 | 61 | 46140 | 19628 | 70862615 |
Application site pruritus | 46.28 | 10.71 | 29 | 46172 | 3572 | 70878671 |
Systemic lupus erythematosus | 43.67 | 10.71 | 7 | 46194 | 101895 | 70780348 |
Joint swelling | 43.38 | 10.71 | 61 | 46140 | 253150 | 70629093 |
Off label use | 42.84 | 10.71 | 296 | 45905 | 742764 | 70139479 |
Dysuria | 42.62 | 10.71 | 93 | 46108 | 45701 | 70836542 |
Balance disorder | 42.21 | 10.71 | 142 | 46059 | 89986 | 70792257 |
Bladder disorder | 41.56 | 10.71 | 38 | 46163 | 8251 | 70873992 |
Drug intolerance | 40.03 | 10.71 | 53 | 46148 | 225634 | 70656609 |
Nephrolithiasis | 39.46 | 10.71 | 92 | 46109 | 47231 | 70835012 |
Maternal exposure during pregnancy | 39.37 | 10.71 | 13 | 46188 | 115332 | 70766911 |
White blood cells urine positive | 38.80 | 10.71 | 31 | 46170 | 5609 | 70876634 |
Pollakiuria | 37.06 | 10.71 | 73 | 46128 | 33388 | 70848855 |
Hallucination | 36.46 | 10.71 | 121 | 46080 | 76139 | 70806104 |
Culture urine positive | 35.08 | 10.71 | 26 | 46175 | 4211 | 70878032 |
Infusion related reaction | 34.41 | 10.71 | 47 | 46154 | 197487 | 70684756 |
Incontinence | 33.67 | 10.71 | 42 | 46159 | 12986 | 70869257 |
Muscular weakness | 33.37 | 10.71 | 178 | 46023 | 138158 | 70744085 |
Depression | 31.64 | 10.71 | 230 | 45971 | 198744 | 70683499 |
Urine leukocyte esterase positive | 31.61 | 10.71 | 23 | 46178 | 3622 | 70878621 |
Cystitis | 31.50 | 10.71 | 84 | 46117 | 46857 | 70835386 |
Hepatic enzyme increased | 30.87 | 10.71 | 34 | 46167 | 156956 | 70725287 |
Bacterial test | 29.83 | 10.71 | 15 | 46186 | 1208 | 70881035 |
Gait inability | 29.24 | 10.71 | 82 | 46119 | 47093 | 70835150 |
Urinary tract infection bacterial | 29.16 | 10.71 | 26 | 46175 | 5465 | 70876778 |
Glossodynia | 29.07 | 10.71 | 10 | 46191 | 86477 | 70795766 |
Interstitial lung disease | 29.02 | 10.71 | 16 | 46185 | 104669 | 70777574 |
Secondary progressive multiple sclerosis | 28.25 | 10.71 | 15 | 46186 | 1352 | 70880891 |
Asthenia | 28.08 | 10.71 | 436 | 45765 | 457230 | 70425013 |
Urinary sediment present | 27.92 | 10.71 | 18 | 46183 | 2329 | 70879914 |
Decubitus ulcer | 27.85 | 10.71 | 40 | 46161 | 14151 | 70868092 |
Hallucination, visual | 26.64 | 10.71 | 59 | 46142 | 29278 | 70852965 |
Exposure during pregnancy | 26.43 | 10.71 | 12 | 46189 | 87705 | 70794538 |
Syncope | 25.45 | 10.71 | 190 | 46011 | 165519 | 70716724 |
Impaired self-care | 25.43 | 10.71 | 17 | 46184 | 2337 | 70879906 |
Urine abnormality | 24.76 | 10.71 | 28 | 46173 | 7810 | 70874433 |
Hepatic function abnormal | 24.39 | 10.71 | 7 | 46194 | 67989 | 70814254 |
Malignant neoplasm progression | 24.34 | 10.71 | 26 | 46175 | 121713 | 70760530 |
Cerebral atrophy | 23.91 | 10.71 | 27 | 46174 | 7520 | 70874723 |
Granulocytopenia | 23.87 | 10.71 | 32 | 46169 | 10615 | 70871628 |
General physical health deterioration | 23.56 | 10.71 | 77 | 46124 | 235954 | 70646289 |
Urine oxalate increased | 23.54 | 10.71 | 8 | 46193 | 235 | 70882008 |
Amnesia | 23.38 | 10.71 | 81 | 46120 | 52074 | 70830169 |
Intestinal pseudo-obstruction | 23.21 | 10.71 | 16 | 46185 | 2314 | 70879929 |
Myelocyte percentage increased | 23.19 | 10.71 | 8 | 46193 | 246 | 70881997 |
Delirium | 22.99 | 10.71 | 103 | 46098 | 74511 | 70807732 |
Application site rash | 22.90 | 10.71 | 15 | 46186 | 1994 | 70880249 |
Band neutrophil percentage increased | 22.82 | 10.71 | 9 | 46192 | 406 | 70881837 |
Dementia | 22.63 | 10.71 | 47 | 46154 | 22318 | 70859925 |
Dizziness | 22.58 | 10.71 | 426 | 45775 | 463715 | 70418528 |
Thrombocytopenia | 22.51 | 10.71 | 80 | 46121 | 239030 | 70643213 |
Hallucinations, mixed | 22.30 | 10.71 | 24 | 46177 | 6338 | 70875905 |
Abdominal discomfort | 22.15 | 10.71 | 69 | 46132 | 214589 | 70667654 |
Dysmetropsia | 21.76 | 10.71 | 6 | 46195 | 85 | 70882158 |
Pyelonephritis | 21.60 | 10.71 | 41 | 46160 | 18248 | 70863995 |
Urosepsis | 21.56 | 10.71 | 48 | 46153 | 23901 | 70858342 |
Febrile neutropenia | 21.56 | 10.71 | 65 | 46136 | 204253 | 70677990 |
Retinal depigmentation | 21.34 | 10.71 | 8 | 46193 | 314 | 70881929 |
Faecaloma | 21.31 | 10.71 | 30 | 46171 | 10421 | 70871822 |
Constipation | 20.97 | 10.71 | 254 | 45947 | 252184 | 70630059 |
Duodenal ulcer perforation | 20.83 | 10.71 | 4 | 46197 | 51108 | 70831135 |
Red blood cells urine positive | 20.57 | 10.71 | 20 | 46181 | 4689 | 70877554 |
Stress urinary incontinence | 20.27 | 10.71 | 13 | 46188 | 1667 | 70880576 |
Monocyte percentage increased | 20.27 | 10.71 | 14 | 46187 | 2031 | 70880212 |
Crystal urine present | 20.16 | 10.71 | 14 | 46187 | 2048 | 70880195 |
Specific gravity urine decreased | 19.59 | 10.71 | 10 | 46191 | 831 | 70881412 |
Daydreaming | 19.54 | 10.71 | 10 | 46191 | 836 | 70881407 |
Disorganised speech | 19.44 | 10.71 | 13 | 46188 | 1788 | 70880455 |
Wound | 18.73 | 10.71 | 22 | 46179 | 98710 | 70783533 |
Arthropathy | 18.66 | 10.71 | 44 | 46157 | 150013 | 70732230 |
Band neutrophil count increased | 18.59 | 10.71 | 9 | 46192 | 668 | 70881575 |
Lymphocyte percentage decreased | 18.48 | 10.71 | 19 | 46182 | 4760 | 70877483 |
Body height decreased | 18.39 | 10.71 | 24 | 46177 | 7759 | 70874484 |
Bladder pain | 18.19 | 10.71 | 13 | 46188 | 1991 | 70880252 |
Folliculitis | 18.06 | 10.71 | 3 | 46198 | 42567 | 70839676 |
Renal impairment | 18.06 | 10.71 | 42 | 46159 | 143895 | 70738348 |
Food refusal | 17.86 | 10.71 | 8 | 46193 | 497 | 70881746 |
Product adhesion issue | 17.63 | 10.71 | 14 | 46187 | 2510 | 70879733 |
Rash | 17.50 | 10.71 | 231 | 45970 | 510331 | 70371912 |
Abnormal behaviour | 17.41 | 10.71 | 56 | 46145 | 34653 | 70847590 |
Injection related reaction | 17.23 | 10.71 | 9 | 46192 | 785 | 70881458 |
Product use issue | 17.07 | 10.71 | 60 | 46141 | 179877 | 70702366 |
Pericarditis | 17.03 | 10.71 | 18 | 46183 | 84687 | 70797556 |
Dermatitis contact | 17.00 | 10.71 | 26 | 46175 | 9723 | 70872520 |
Dysarthria | 16.98 | 10.71 | 83 | 46118 | 62230 | 70820013 |
Vision blurred | 16.96 | 10.71 | 113 | 46088 | 94871 | 70787372 |
Multiple organ dysfunction syndrome | 16.78 | 10.71 | 28 | 46173 | 108487 | 70773756 |
Stomatitis | 16.53 | 10.71 | 37 | 46164 | 128474 | 70753769 |
Memory impairment | 16.42 | 10.71 | 110 | 46091 | 92531 | 70789712 |
Urinary tract infection pseudomonal | 16.35 | 10.71 | 11 | 46190 | 1528 | 70880715 |
Drug abuse | 16.14 | 10.71 | 46 | 46155 | 147210 | 70735033 |
Product use in unapproved indication | 16.02 | 10.71 | 75 | 46126 | 207403 | 70674840 |
Neutropenia | 15.97 | 10.71 | 100 | 46101 | 257056 | 70625187 |
Lagophthalmos | 15.95 | 10.71 | 7 | 46194 | 414 | 70881829 |
Psychotic symptom | 15.92 | 10.71 | 13 | 46188 | 2425 | 70879818 |
Bone marrow failure | 15.90 | 10.71 | 6 | 46195 | 49004 | 70833239 |
Swelling | 15.86 | 10.71 | 66 | 46135 | 188473 | 70693770 |
Hydronephrosis | 15.39 | 10.71 | 32 | 46169 | 15210 | 70867033 |
Application site vesicles | 15.31 | 10.71 | 10 | 46191 | 1323 | 70880920 |
Visual impairment | 15.26 | 10.71 | 97 | 46104 | 80153 | 70802090 |
Nocturia | 15.21 | 10.71 | 28 | 46173 | 12176 | 70870067 |
Product dose omission issue | 15.19 | 10.71 | 212 | 45989 | 217256 | 70664987 |
Urge incontinence | 14.76 | 10.71 | 9 | 46192 | 1056 | 70881187 |
Repetitive strain injury | 14.74 | 10.71 | 5 | 46196 | 146 | 70882097 |
Myelocyte count increased | 14.69 | 10.71 | 8 | 46193 | 759 | 70881484 |
Blister | 14.58 | 10.71 | 27 | 46174 | 100499 | 70781744 |
Drug reaction with eosinophilia and systemic symptoms | 14.50 | 10.71 | 10 | 46191 | 58003 | 70824240 |
Thyroglobulin increased | 14.42 | 10.71 | 4 | 46197 | 58 | 70882185 |
Toxic epidermal necrolysis | 14.32 | 10.71 | 4 | 46197 | 39553 | 70842690 |
Urine odour abnormal | 14.27 | 10.71 | 18 | 46183 | 5625 | 70876618 |
Urinary tract disorder | 14.25 | 10.71 | 14 | 46187 | 3323 | 70878920 |
Speech disorder | 14.23 | 10.71 | 68 | 46133 | 50512 | 70831731 |
Somnolence | 14.18 | 10.71 | 208 | 45993 | 215398 | 70666845 |
Progressive multiple sclerosis | 14.13 | 10.71 | 8 | 46193 | 818 | 70881425 |
Product administered at inappropriate site | 14.12 | 10.71 | 14 | 46187 | 3362 | 70878881 |
Therapeutic product effect decreased | 14.03 | 10.71 | 47 | 46154 | 142971 | 70739272 |
Red blood cell sedimentation rate increased | 13.82 | 10.71 | 4 | 46197 | 38638 | 70843605 |
Haemoglobin urine present | 13.77 | 10.71 | 8 | 46193 | 859 | 70881384 |
Cystitis interstitial | 13.71 | 10.71 | 9 | 46192 | 1200 | 70881043 |
Anticholinergic syndrome | 13.66 | 10.71 | 13 | 46188 | 2967 | 70879276 |
Liver disorder | 13.63 | 10.71 | 12 | 46189 | 61556 | 70820687 |
Prescription drug used without a prescription | 13.60 | 10.71 | 13 | 46188 | 2984 | 70879259 |
Head injury | 13.58 | 10.71 | 51 | 46150 | 34090 | 70848153 |
Perthes disease | 13.48 | 10.71 | 3 | 46198 | 16 | 70882227 |
Open fracture | 13.10 | 10.71 | 6 | 46195 | 393 | 70881850 |
Cerebrovascular accident | 13.07 | 10.71 | 147 | 46054 | 143323 | 70738920 |
Shock | 13.03 | 10.71 | 5 | 46196 | 40420 | 70841823 |
Wrist fracture | 12.95 | 10.71 | 24 | 46177 | 10492 | 70871751 |
Arthralgia | 12.77 | 10.71 | 241 | 45960 | 503149 | 70379094 |
Product complaint | 12.72 | 10.71 | 26 | 46175 | 12205 | 70870038 |
Cytomegalovirus infection | 12.68 | 10.71 | 5 | 46196 | 39753 | 70842490 |
Lymphocyte count decreased | 12.59 | 10.71 | 59 | 46142 | 43480 | 70838763 |
Lethargy | 12.53 | 10.71 | 88 | 46113 | 75162 | 70807081 |
Blood urine present | 12.35 | 10.71 | 34 | 46167 | 19319 | 70862924 |
Neutrophil percentage increased | 12.31 | 10.71 | 15 | 46186 | 4527 | 70877716 |
Lower respiratory tract infection | 12.23 | 10.71 | 35 | 46166 | 111878 | 70770365 |
Kidney infection | 12.23 | 10.71 | 34 | 46167 | 19421 | 70862822 |
Injection site scar | 12.17 | 10.71 | 7 | 46194 | 738 | 70881505 |
Occupational exposure to product | 12.08 | 10.71 | 7 | 46194 | 748 | 70881495 |
Haematocrit decreased | 12.02 | 10.71 | 71 | 46130 | 57187 | 70825056 |
Drug ineffective | 11.94 | 10.71 | 496 | 45705 | 939256 | 69942987 |
Ascites | 11.82 | 10.71 | 16 | 46185 | 67531 | 70814712 |
Incision site pruritus | 11.75 | 10.71 | 3 | 46198 | 31 | 70882212 |
Acute myeloid leukaemia | 11.44 | 10.71 | 3 | 46198 | 30937 | 70851306 |
Anaemia folate deficiency | 11.34 | 10.71 | 5 | 46196 | 299 | 70881944 |
Insomnia | 11.29 | 10.71 | 202 | 45999 | 217604 | 70664639 |
Central nervous system lesion | 11.25 | 10.71 | 25 | 46176 | 12428 | 70869815 |
Skin ulcer | 11.13 | 10.71 | 9 | 46192 | 48136 | 70834107 |
Salivary gland disorder | 11.07 | 10.71 | 5 | 46196 | 317 | 70881926 |
Hip fracture | 11.06 | 10.71 | 42 | 46159 | 28221 | 70854022 |
Porphyria acute | 10.93 | 10.71 | 8 | 46193 | 1271 | 70880972 |
Ankle fracture | 10.84 | 10.71 | 28 | 46173 | 15316 | 70866927 |
Tongue haemorrhage | 10.77 | 10.71 | 7 | 46194 | 918 | 70881325 |
None
Source | Code | Description |
---|---|---|
ATC | G04BD04 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence |
FDA MoA | N0000000125 | Cholinergic Muscarinic Antagonists |
MeSH PA | D018678 | Cholinergic Agents |
MeSH PA | D018680 | Cholinergic Antagonists |
MeSH PA | D018727 | Muscarinic Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D010276 | Parasympatholytics |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D064804 | Urological Agents |
CHEBI has role | CHEBI:36333 | local anesthetics |
CHEBI has role | CHEBI:38215 | calcium channel blockers |
CHEBI has role | CHEBI:48876 | muscarinic antagonists |
CHEBI has role | CHEBI:50370 | parasympatholytics |
CHEBI has role | CHEBI:51371 | muscle relaxants |
CHEBI has role | CHEBI:53784 | antispasmodics |
FDA EPC | N0000175700 | Cholinergic Muscarinic Antagonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Urgent desire to urinate | indication | 75088002 | |
Urge incontinence of urine | indication | 87557004 | |
Bladder muscle dysfunction - overactive | indication | 236633002 | |
Neurogenic bladder | indication | 398064005 | |
Increased Urinary Frequency | indication | ||
Sinus tachycardia | contraindication | 11092001 | |
Severe chronic ulcerative colitis | contraindication | 14311001 | |
Toxic megacolon | contraindication | 28536002 | DOID:1770 |
Atony of colon | contraindication | 29479008 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Conduction disorder of the heart | contraindication | 44808001 | |
Chronic heart failure | contraindication | 48447003 | |
Paralytic ileus | contraindication | 55525008 | DOID:8442 |
Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
Hiatal hernia | contraindication | 84089009 | DOID:12642 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Gastrointestinal obstruction | contraindication | 126765001 | |
Gastroesophageal reflux disease | contraindication | 235595009 | DOID:8534 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Bladder outflow obstruction | contraindication | 236645006 | |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Retention of urine | contraindication | 267064002 | |
Drowsy | contraindication | 271782001 | |
Gastric retention | contraindication | 307227006 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Disorder of coronary artery | contraindication | 414024009 | |
Gastrointestinal hypomotility | contraindication | 421807004 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.67 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
10% (100MG/PACKET) | GELNIQUE | ALLERGAN | N022204 | Jan. 27, 2009 | RX | GEL | TRANSDERMAL | 10449173 | Nov. 6, 2029 | TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL |
10% (100MG/PACKET) | GELNIQUE | ALLERGAN | N022204 | Jan. 27, 2009 | RX | GEL | TRANSDERMAL | 9259388 | Nov. 6, 2029 | TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN |
10% (100MG/PACKET) | GELNIQUE | ALLERGAN | N022204 | Jan. 27, 2009 | RX | GEL | TRANSDERMAL | 8920392 | March 26, 2031 | TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Muscarinic acetylcholine receptor M1 | GPCR | ANTAGONIST | Ki | 9 | CHEMBL | DRUG LABEL | |||
Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | Ki | 9.11 | CHEMBL | DRUG LABEL | |||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.59 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.30 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 6.84 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | ANTAGONIST | Ki | 8.09 | CHEMBL | ||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 8.44 | CHEMBL | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 7.17 | DRUG MATRIX | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 6.22 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.85 | CHEMBL | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.99 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 8.23 | CHEMBL | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 6.09 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 8.16 | CHEMBL | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 9.02 | CHEMBL |
ID | Source |
---|---|
4018815 | VUID |
N0000147118 | NUI |
D00465 | KEGG_DRUG |
1508-65-2 | SECONDARY_CAS_RN |
4018815 | VANDF |
4019869 | VANDF |
C0069805 | UMLSCUI |
CHEBI:7856 | CHEBI |
CHEMBL1231 | ChEMBL_ID |
CHEMBL1133 | ChEMBL_ID |
DB01062 | DRUGBANK_ID |
C005419 | MESH_SUPPLEMENTAL_RECORD_UI |
4634 | PUBCHEM_CID |
359 | IUPHAR_LIGAND_ID |
1354 | INN_ID |
K9P6MC7092 | UNII |
151651 | RXNORM |
180 | MMSL |
28244 | MMSL |
4610 | MMSL |
46359 | MMSL |
5214 | MMSL |
d00328 | MMSL |
001768 | NDDF |
004715 | NDDF |
31815007 | SNOMEDCT_US |
35768004 | SNOMEDCT_US |
372717000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
GELNIQUE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5812 | GEL | 100 mg | TRANSDERMAL | NDA | 27 sections |
GELNIQUE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5812 | GEL | 100 mg | TRANSDERMAL | NDA | 27 sections |
GELNIQUE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5861 | GEL | 100 mg | TRANSDERMAL | NDA | 27 sections |
GELNIQUE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5861 | GEL | 100 mg | TRANSDERMAL | NDA | 27 sections |
OXYTROL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-6153 | PATCH | 3.90 mg | TRANSDERMAL | NDA | 27 sections |
Oxytrol for Women | HUMAN OTC DRUG LABEL | 1 | 0023-9637 | PATCH | 3.90 mg | TRANSDERMAL | NDA | 14 sections |
OXYBUTYNIN CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0671 | SYRUP | 5 mg | ORAL | ANDA | 18 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0603-4975 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0603-4975 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-3512 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-3512 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
oxybutynin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8219 | TABLET, FILM COATED, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 24 sections |
Oxybutynin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8220 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 24 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8428 | TABLET | 5 mg | ORAL | ANDA | 20 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0038 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-2821 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6570 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 25 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6570 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 25 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7027 | TABLET | 5 mg | ORAL | ANDA | 20 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-609 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 29 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-610 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 29 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-611 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 29 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-640 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-518 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-559 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-201 | TABLET | 5 mg | ORAL | ANDA | 22 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14539-653 | TABLET | 5 mg | ORAL | ANDA | 13 sections |
oxybutynin chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-317 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 26 sections |
oxybutynin chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-318 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
oxybutynin chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-319 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 26 sections |